M1 Polypeptide Influenza Vaccine for Broad Strain Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current influenza vaccines require yearly reformulation due to high variability in surface-expressed viral proteins, leading to increased production costs and limited availability, and they do not provide long-lasting protection against new strains, especially during pandemics.
Innovation Solution
Development of M1 polypeptides from the C-terminal region of the influenza M1 protein, which are surface-exposed and capable of interacting with neutralizing antibodies and immune cells, used to create a vaccine that induces a protective immune response and can be produced in large quantities for efficient distribution and administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current influenza vaccines are used, then they can provide seasonal protection, but they require yearly reformulation due to high variability in surface-expressed viral proteins, leading to increased production costs and limited availability
Solution Approach 1:
The patent extracts the M1 polypeptide from the variable surface proteins (HA and NA) that require yearly reformulation. By focusing on the conserved M1 protein instead of the variable surface glycoproteins, the vaccine achieves stability across different influenza strains without requiring annual updates, thereby reducing production costs and improving availability while maintaining protective effectiveness.
Solution Approach 2:
The M1 polypeptide serves as a universal antigen that provides protection against multiple influenza strains simultaneously. Unlike traditional vaccines that target specific HA and NA subtypes requiring yearly updates, the M1-based vaccine offers broad-spectrum protection across different influenza A and B strains, functioning as a multi-functional solution that addresses both seasonal and pandemic threats.
2Adaptability or versatility
If current influenza vaccines are reformulated yearly to match new strains, then they can maintain protection against circulating strains, but they do not provide long-lasting protection against new strains, especially during pandemics
Solution Approach 1:
The M1 polypeptide vaccine provides preliminary, long-lasting immunity that persists across multiple influenza seasons and strain variations. By establishing durable immune memory against the conserved M1 protein, the vaccine creates a foundation of protection that remains effective even when new strains emerge, eliminating the need for yearly reformulation while maintaining adaptability to new threats.
Solution Approach 2:
Instead of targeting the variable surface proteins that change yearly (HA and NA), the patent inverts the approach by targeting the conserved internal M1 protein that remains relatively stable across strains. This inversion strategy shifts the focus from adapting to change yearly to leveraging stability for long-lasting protection, while still providing adaptability through cross-strain recognition.
3Duration of action of moving object
If M1 polypeptides are used to create a vaccine, then long-lasting protection against influenza can be achieved, but new production and distribution systems must be established
Solution Approach 1:
The M1 polypeptide can be produced through recombinant DNA technology, creating standardized copies of the antigen that can be manufactured consistently across different production facilities. This copying approach enables scalable production using established biotechnology platforms, reducing the complexity of establishing entirely new production systems while achieving long-lasting protection through consistent antigen quality.
Data Source
AI summary
The present invention is directed generally to M1 polypeptides that can be utilized as vaccines and/or antigens for generation of anti-M1 polypeptide antibodies for prophylactic treatment of individuals who are susceptible to infection by influenza virus. The anti-M1 polypeptide antibodies of the invention are useful for treatment of individuals infected with influenza virus, or useful for prophylactic treatment of individuals who are susceptible to infection by influenza virus, or for immune-suppressed individuals who cannot generate an effective antibody response.